Overview
John Strickler, MD is a Professor of Medicine in the Division of Medical Oncology, where he is Co-Leader for the Precision Cancer Medicine and Investigational Therapeutics Program at the Duke Cancer Institute, Leader of the Molecular Tumor Board, and Associate Director of Clinical Research – GI Oncology. Dr. Strickler’s clinic specializes on the treatment of gastrointestinal malignancies, with a particular emphasis on gastroesophageal, pancreatic, and colorectal cancers. His research focuses on precision cancer medicine: identification of biomarkers that predict sensitivity or resistance to targeted therapies and immunotherapy. He has designed and executed clinical trials that test novel therapies and innovative therapeutic strategies. He was Principal Investigator on an investigator sponsored trial that led to the first FDA-approved therapy for HER2+ metastatic colorectal cancer. He has first-author publications in several high impact factor medical journals, including the New England Journal of Medicine, Clinical Cancer Research, Cancer Discovery, Journal of Clinical Oncology, and Lancet Oncology. Nationally, he has served as a member of the American Society of Clinical Oncology (ASCO) Treatment Guidelines Committee for Advanced Colon Cancer.
Current Appointments & Affiliations
Professor of Medicine
·
2024 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2008 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations.
Journal Article Oncologist · June 4, 2025 BACKGROUND: FGFR alterations are known to be driver alterations in several tumor types. We aimed to assess the efficacy of pemigatinib, an oral FGFR1-3 inhibitor, in patients with metastatic or unresectable colorectal cancer whose tumors harbored FGF/FGFR ... Full text Link to item CiteSupplementary Table 1 from Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina
Other · April 3, 2025 <p>Supplementary Tables S1a-S1d show estimates for the association between any genomic testing and race and ethnicity among non-Hispanic Black and non-Hispanic White patients by cancer type</p> ... Full text CiteRecent Grants
QTX3544-201 A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of QTX3544 in Patients with Advanced Solid Tumors with KRASG12V Mutations
Clinical TrialPrincipal Investigator · Awarded by Quanta Therapeutics, Inc. · 2025 - 2030A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid Tumors (J5Q-OX-JRDA)
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2030J5J-OX-JZZA A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2030View All Grants
Education, Training & Certifications
The University of Chicago ·
2005
M.D.